¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

2022³â ´ëÇѹÙÀÌ·¯½ºÇÐȸ Á¤±âÇмú´ëȸ : 2022-08-27

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
2022³â ´ëÇѹÙÀÌ·¯½ºÇÐȸ Á¤±âÇмú´ëȸ : 2022-08-27
±³À°ÀÏÀÚ : 2022-08-27
±³À°Àå¼Ò : À»ÁöÀη°³¹ß¿ø  
±³À°ÁÖÁ¦ : 2022³â ´ëÇѹÙÀÌ·¯½ºÇÐȸ Á¤±âÇмú´ëȸ
ÁÖÃÖ±â°ü : ´ëÇѹÙÀÌ·¯½ºÇÐȸ
´ã´çÀÚ : ÃÖ¼¼ÀÎ
¿¬¶ôó : 070-8886-3062  
À̸ÞÀÏ : virology@ksov.org      
±³À°Á¾·ù : ÀÇ»çÇйýÀÇÇп¹¹æÀÇÇÐÇغÎÇлý¸®ÇлýÈ­ÇкÐÀÚ»ý¹°Çй̻ý¹°Çбâ»ýÃæÇоฮÇР     
Âü¼®¿¹»óÀοø : 250¸í
Èñ¸ÁÆòÁ¡ : 5Á¡  
Áö¿ª : °­¿øµµ
±³À°½Ã°£ : 5 ½Ã°£ 5ºÐ  
¼¼ºÎ¼ö°­·á : 200,000¿ø      
ºñ°í ÆòÀÇ¿ø: ÀÏ¹Ý 20¸¸¿ø, Çлý 8¸¸¿ø Á¤È¸¿ø: ÀÏ¹Ý 15¸¸¿ø, Çлý 8¸¸¿ø ºñȸ¿ø: ÀÏ¹Ý 15¸¸¿ø, Çлý 8¸¸¿ø ÇöÀåµî·Ï: ÀÏ¹Ý 20¸¸¿ø, Çлý 10¸¸¿ø      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 08-27 ´ë°­ÀǽǠ09:30~09:50 Modeling how peginterferon alfa improves clearance rates of cccDNA in hepatitis B virus infected patients  ±è±¤¼ö(ºÎ°æ´ëÇб³ °úÇнýºÅ۽ùķ¹À̼ÇÇаú) 
±³À°½Ã°£ 08-27 ´ë°­ÀǽǠ09:50~10:10 Antiviral activity of activated cdc42-associated kinase 1 against hepatitis B virus  ¹Ú¿ë±¤(±¹¸³º¸°Ç¿ø ¸¸¼º¹ÙÀÌ·¯½º¿¬±¸°ú) 
±³À°½Ã°£ 08-27 ´ë°­ÀǽǠ10:10~10:30 Role of p62/SQSTM1 in ZIKV Pathogenesis  ±è¼ºÁØ(Çѱ¹È­Çבּ¸¿ø) 
±³À°½Ã°£ 08-27 ´ë°­ÀǽǠ10:30~10:45 SARS-CoV-2 productively infects human hepatocytes and induces cell death  °íõ±Ô(Çѱ¹È­Çבּ¸¿ø) 
±³À°½Ã°£ 08-27 ´ë°­ÀǽǠ10:45~11:00 Host sensing of RNA viruses and the viral evasion strategies: From fundamental mechanism study to the development of the screening tool  À¯Áö½Â(±âÃÊ°úÇבּ¸¿ø Çѱ¹¹ÙÀÌ·¯½º±âÃÊ¿¬±¸¼Ò) 
±³À°½Ã°£ 08-27 ´ë°­ÀǽǠ11:00~11:15 CaMKII Inhibits HBV Replication via AMPK/AKT/mTOR Signaling pathways  ±èÁÖ¹Ì(¾ÆÁÖ´ëÇб³ ÀÇ°ú´ëÇÐ) 
±³À°½Ã°£ 08-27 ´ë°­ÀǽǠ11:15~11:30 The regulatory T cell population is not normalized following successfultreatment of chronic hepatitis C with direct-acting antivirals  ±è¼Ò¿µ(KAIST) 
±³À°½Ã°£ 08-27 ´ë°­ÀǽǠ13:05~13:30 Viral G-quadruplex as a promising target to control SARS-CoV-2 infection  ¼Û¹®Á¤(°í·Á´ëÇб³ »ý¸í°úÇдëÇÐ) 
±³À°½Ã°£ 08-27 ´ë°­ÀǽǠ13:30~13:55 Preparedness against Viral Disease X with active surveillance from wild life animals and nanobiotechnology for diagnosis, antiviral, and vaccine  ¼Û´ë¼·(¼­¿ï´ëÇб³ ¼öÀÇ°ú´ëÇÐ) 
±³À°½Ã°£ 08-27 ´ë°­ÀǽǠ13:55~14:20 Influenza and SARS-CoV-2 co-infection alters viral tropism in Syrian hamsters  À±¼±¿ì(Çѱ¹»ý¸í°øÇבּ¸¿ø) 
Åä·Ð 08-27 ´ë°­ÀǽǠ14:20~14:40 ÁúÀÇÀÀ´ä  () 
±³À°½Ã°£ 08-27 ´ë°­ÀǽǠ14:40~14:52 SARS-CoV-2 omicron mainly utilizes cathepsin for infectivity and fusogenicity  ÀåÀǼø(°í·Á´ëÇб³ »ý¸íÁ¤º¸Çаú) 
±³À°½Ã°£ 08-27 ´ë°­ÀǽǠ14:52~15:04 Definition and correlation analysis of bimodal distribution of sequencing data of transcriptome and chromatin accessibility  ±è±¤ÈÆ(¼­¿ï´ëÇб³ ÀÇ°ú´ëÇÐ) 
±³À°½Ã°£ 08-27 ´ë°­ÀǽǠ15:04~15:16 Single Cell Transcriptomic Analysis of Human Lung Organoids to model SARS-CoV-2 Infection  À̼¼À±(¼­¿ï´ëÇб³ ÀÇ°ú´ëÇÐ) 
±³À°½Ã°£ 08-27 ´ë°­ÀǽǠ15:16~15:28 Aging dependent Immunopathology of the COVID-19 : The potent guardians, Innate lymphoid cells  Àӹοµ(¼­¿ï´ëÇб³ ÀÇ°ú´ëÇÐ) 
±³À°½Ã°£ 08-27 ´ë°­ÀǽǠ15:28~15:40 Development of humanized ACE2-expressing mouse model for COVID-19  ¹Ú¿îÀÌ(¼­¿ï´ëÇб³ ÀÇ°ú´ëÇÐ) 
±³À°½Ã°£ 08-27 ´ë°­ÀǽǠ15:40~15:52 Mutation patterns of SARS-CoV-2 through serial passage in human cell lines  ³ëÁö¿µ(ÃæºÏ´ëÇб³ »ý¸í½Ã½ºÅÛÇаú) 
Åä·Ð 08-27 ´ë°­ÀǽǠ15:52~16:10 ÁúÀÇÀÀ´ä  () 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" 2022³â ´ëÇѹÙÀÌ·¯½ºÇÐȸ Á¤±âÇмú´ëȸ : 2022-08-27""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û 2022³âµµ ´ëÇѽŰæ¿Ü°úÇÐȸ ´ë±¸¡¤°æºÏÁöȸ Á¦3Â÷ ¿¬¼ö±³À° : 2022-08-27
´ÙÀ½±Û 2022 ´ëÇÑ°ñ´ë»çÇÐȸ °ñ¼øȯ ½ÉÆ÷Áö¿ò (The 21st International Symposium of Association Research Circulation Osseous)(2ÀÏÂ÷) : 2022-08-27
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
164 ¼­¿ï ´ëÇѺñ´¢±â°úÇÐȸ 2018 KPS-APSU Joint International Symposium : 2018-08-31 0 1,288 2018-07-28
163 °­¿ø ´ëÇѽŻý¾ÆÇÐȸ Á¦9Â÷ ±³À°¼¼¹Ì³ª¥° : 2018-08-31 0 482 2018-07-28
162 Àü³² 2018 ¿ø±¤´ëÇб³º´¿ø ±Ç¿ª¿Ü»ó¼¾ÅÍ ½ÉÆ÷Áö¾ö ¹× The 3rd MERIT Symposium : 2018-08-31 0 708 2018-07-28
161 ¼­¿ï 2018³â Á¦6ȸ ´ë¾ÈºÒ¾ÈÀÇÇÐȸ ¿¬¼ö±³À° : 2018-08-31 0 539 2018-07-28
160 ¼­¿ï ¿øÀڷº´¿ø 2018³âµµ 2Â÷ ¹æ»ç¼±ºñ»óÁø·á ½Å±Ô±³À° (2ÀÏÂ÷) : 2018-08-31 0 616 2018-07-28
159 ¼­¿ï ´ëÇѼºÇü¿Ü°úÇÐȸ ±âÃÊÀÇÇבּ¸ È°¼ºÈ­ ¹× Ãʺ¸ÀÚ¸¦ À§ÇÑ ÄÁÆÛ·±½º : 2018-08-31 0 484 2018-07-28
158 ¼­¿ï °í·Á´ëÇб³±¸·Îº´¿ø 1) °áÇÕÁ¶Á÷ Áúȯ 2) ÇǺÎÁö¹æ Áúȯ : 2018-08-30 0 672 2018-07-28
157 ¼­¿ï Çѱ¹³ú½Å°æ°úÇÐȸ Knowing Brain, Healing Brain : 2018-08-30 0 502 2018-07-28
156 ºÎ»ê 2018 ´ëÇÑÁ¶Ç÷¸ð¼¼Æ÷À̽ÄÇÐȸ ±¹Á¦Çмú´ëȸ(8¿ù 30ÀÏ) : 2018-08-30 0 598 2018-07-28
155 ¼­¿ï ´ëÇÑÀÇ»çÇùȸ [Á¦27±â ÀÇ·áÁ¤Ã¥ÃÖ°íÀ§°úÁ¤] 3Â÷ »ó´ë°¡Ä¡ °³Æí : 2018-08-30 0 1,002 2018-07-28
154 ¼­¿ï ¿øÀڷº´¿ø 2018³âµµ 2Â÷ ¹æ»ç¼±ºñ»óÁø·á ½Å±Ô±³À° (1ÀÏÂ÷) : 2018-08-30 0 932 2018-07-28
153 ºÎ»ê ´ëÇѾȰúÇÐȸ ÇмúÁý´ãȸ(³ì³»Àå, New trends of glaucoma treatment) : 2018-08-30 0 917 2018-07-28
152 °æ±â Çϳ²½Ã ÀÇ»çȸ ¿¬¼ö°­ÁÂ(Ç÷°ü¼ºÄ¡¸Å, °¨¿°³»°ú °¨¿°Áúȯ) : 2018-08-30 0 2,098 2018-07-28
151 ¼­¿ï ÀÎÁ¦´ëÇб³»ó°è¹éº´¿ø °¢¸· Áúȯ : 2018-08-29 0 762 2018-07-28
150 ´ë±¸ ´ë±¸°¡Å縯´ëÇб³º´¿ø Ȳ¹ÝºÎÁ¾ ¹× Ȳ¹Ýº¯¼º : 2018-08-28 0 692 2018-07-28
1401 | 1402 | 1403 | 1404 | 1405 | 1406 | 1407 | 1408 | 1409 | 1410
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷